Biotechnology & Pharma: 2018 Investment Budget in R&D – Top Ten Companies, Top R&D% AZ, Merck, BMS, Eli Lilly
Reporter: Aviva Lev-Ari, PhD, RN
AstraZeneca Budget 5,932,000,000 R&D 5,932,000,000 27.0%
Merck Budget 9,750,000,000 R&D 9,750,000,000 23.0%
BMS Budget 6,345,000,000 R&D 6,345,000,000 23.0%
Eli Lilly Budget 5,307,100,000 R&D 5,307,100,000 22.5%
The top 10 pharma R&D budgets in 2018
Annual pharma R&D budgets
Company | Measure Names | SUM(Budget (copy)) | SUM(Budget) | SUM(R&D as percentage of revenue) |
---|---|---|---|---|
GlaxoSmithKline | Budget | 5,196,000,000 | 5,196,000,000 | 12.6 |
Eli Lilly | Budget | 5,307,100,000 | 5,307,100,000 | 22.5 |
AstraZeneca | Budget | 5,932,000,000 | 5,932,000,000 | 27.0 |
Bristol-Myers Squibb | Budget | 6,345,000,000 | 6,345,000,000 | 23.0 |
Sanofi | Budget | 6,961,000,000 | 6,961,000,000 | 17.1 |
Pfizer | Budget | 8,006,000,000 | 8,006,000,000 | 14.9 |
Novartis | Budget | 9,074,000,000 | 9,074,000,000 | 17.5 |
Merck | Budget | 9,750,000,000 | 9,750,000,000 | 23.0 |
Johnson & Johnson | Budget | 10,800,000,000 | 10,800,000,000 | 13.2 |
Roche | Budget | 11,060,000,000 | 11,060,000,000 | 19.3 |
Showing first 20 rows.
SOURCE
Leave a Reply